An adverse trend in five-year overall survival, toxicity and tolerability concerns, and uncertainty regarding the selected dose suggest the benefit-risk profile of Secura Bio, Inc.’s Copiktra (duvelisib) in its current hematologic cancer indications is unfavorable, the US Food and Drug Administration said.
In a briefing document released ahead of a 23 September meeting of the Oncologic Drugs Advisory Committee, the FDA...





